1413431-05-6

Basic information

• Product Name: Ivacaftor-d18
• Synonyms: Ivacaftor-d18;N-[2,4-bis[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-5-hydroxyphenyl]-4-oxo-1H-quinoline-3-carboxamide
• CAS NO: 1413431-05-6
• Molecular Formula: C₂₄H₂₈N₂O₃
• Molecular Weight: 392.49072
• Product Categories: Aromatics, Isotope Labeled Compounds, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1413431-05-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ivacaftor-d18(CAS DataBase Reference)
• NIST Chemistry Reference: Ivacaftor-d18(1413431-05-6)
• EPA Substance Registry System: Ivacaftor-d18(1413431-05-6)

Safety Data

• Hazardous Substances Data: 1413431-05-6(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 1413431-05-6 differently. You can refer to the following data:
1. Ivacaftor-d18 is used in the treatment of cystic fibrosis.
2. Ivacaftor is used in the treatment of cystic fibrosis. This is the labeled analog.

Upstream product

• 1246816-88-5 2-d-4,6-bis(1,1,1,3,3,3-d₆-2-(methyl-d₃)propan-2-yl)phenol 
• 80441-87-8 2,4,6-d₃-phenol-OD 
• 13721-01-2 4-oxo-1,4-dihydroquinoline-3-carboxylic acid 

Relevant articles and documents

DEUTERATED CFTR POTENTIATORS

The present invention relates to a compound of chemical formula I and pharmaceutically acceptable salts thereof. The present invention also provides a composition comprising the compound in the present invention and the use of the composition in a method for treatment of diseases and conditions which are beneficially treated by administering a CFTR potentiator.

DEUTERATED CFTR POTENTIATOR

PROBLEM TO BE SOLVED: To provide compositions comprising novel ivacaftor derivatives and pharmaceutically acceptable salts thereof for treating diseases and conditions that are beneficially treated by administering a CFTR (cystic fibrosis transmembrane co

DEUTERATED CFTR ENHANCEMENT MATERIAL

PROBLEM TO BE SOLVED: To provide a compound to treat cystic fibrosis. SOLUTION: The present invention provides a pharmaceutical composition comprising a compound represented by formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier thereof [X1-X7 independently represent H or D; Y1-Y6 independently represent CH3 or CD3; if all of Y1-Y6 are CH3, at least one of X1-X7 is D]. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT